[1]
Wen WL, Tsai KB, Lin YH, Hwang SJ, Hsiao PJ, Shin SJ, Hung WW. Successful management of type IV hypersensitivity reactions to human insulin analogue with injecting mixtures of biphasic insulin aspart and dexamethasone. Journal of the Formosan Medical Association = Taiwan yi zhi. 2019 Apr:118(4):843-848. doi: 10.1016/j.jfma.2019.01.004. Epub 2019 Jan 28
[PubMed PMID: 30704815]
[2]
You W, Yang J, Liu Y, Wang W, Zhu L, Wang W, Yang J, Chen F. Fulminant type 1 diabetes mellitus: Two case reports. Medicine. 2019 Feb:98(5):e14319. doi: 10.1097/MD.0000000000014319. Epub
[PubMed PMID: 30702611]
Level 3 (low-level) evidence
[3]
Misra S, Mathieu C. Are newer insulin analogues better for people with Type 1 diabetes? Diabetic medicine : a journal of the British Diabetic Association. 2020 Apr:37(4):522-531. doi: 10.1111/dme.13891. Epub 2019 Jan 21
[PubMed PMID: 30585663]
[4]
Dutta D, Mohindra R, Mahajan K, Sharma M. Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis. Diabetes & metabolism journal. 2023 Jan:47(1):72-81. doi: 10.4093/dmj.2022.0035. Epub 2022 Jun 24
[PubMed PMID: 35746893]
Level 1 (high-level) evidence
[5]
Haahr H, Heise T. Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clinical pharmacokinetics. 2020 Feb:59(2):155-172. doi: 10.1007/s40262-019-00834-5. Epub
[PubMed PMID: 31667789]
[6]
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes care. 2023 Jan 1:46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009. Epub
[PubMed PMID: 36507650]
[7]
McCall AL, Lieb DC, Gianchandani R, MacMaster H, Maynard GA, Murad MH, Seaquist E, Wolfsdorf JI, Wright RF, Wiercioch W. Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2023 Feb 15:108(3):529-562. doi: 10.1210/clinem/dgac596. Epub
[PubMed PMID: 36477488]
Level 1 (high-level) evidence
[8]
Kildegaard J, Buckley ST, Nielsen RH, Povlsen GK, Seested T, Ribel U, Olsen HB, Ludvigsen S, Jeppesen CB, Refsgaard HHF, Bendtsen KM, Kristensen NR, Hostrup S, Sturis J. Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. Pharmaceutical research. 2019 Feb 11:36(3):49. doi: 10.1007/s11095-019-2578-7. Epub 2019 Feb 11
[PubMed PMID: 30746556]
[9]
Hsu L, Buckingham B, Basina M, Ekhlaspour L, von Eyben R, Wang J, Lal RA. Fast-Acting Insulin Aspart Use with the MiniMed(TM) 670G System. Diabetes technology & therapeutics. 2021 Jan:23(1):1-7. doi: 10.1089/dia.2020.0083. Epub
[PubMed PMID: 32520594]
[10]
Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. Clinical pharmacokinetics. 2017 May:56(5):551-559. doi: 10.1007/s40262-017-0514-8. Epub
[PubMed PMID: 28205039]
[11]
Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL. Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy. Diabetes technology & therapeutics. 2019 Mar:21(3):101-104. doi: 10.1089/dia.2018.0356. Epub 2019 Jan 28
[PubMed PMID: 30688521]
[12]
Melo KFS, Bahia LR, Pasinato B, Porfirio GJM, Martimbianco AL, Riera R, Calliari LEP, Minicucci WJ, Turatti LAA, Pedrosa HC, Schaan BD. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetology & metabolic syndrome. 2019:11():2. doi: 10.1186/s13098-018-0397-3. Epub 2019 Jan 3
[PubMed PMID: 30622653]
Level 1 (high-level) evidence
[13]
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Jeffrie Seley J, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2023. Diabetes care. 2023 Jan 1:46(Suppl 1):S254-S266. doi: 10.2337/dc23-S015. Epub
[PubMed PMID: 36507645]
[15]
Stamati A, Sotiriou G, Dimitriadou M, Christoforidis A. Efficacy and safety of faster aspart in insulin pumps in children and adolescents with type 1 diabetes mellitus: A single-center study with real-world data. Journal of diabetes and its complications. 2023 Sep:37(9):108587. doi: 10.1016/j.jdiacomp.2023.108587. Epub 2023 Aug 15
[PubMed PMID: 37597378]
[16]
Umpierrez GE, Pasquel FJ. Management of Inpatient Hyperglycemia and Diabetes in Older Adults. Diabetes care. 2017 Apr:40(4):509-517. doi: 10.2337/dc16-0989. Epub
[PubMed PMID: 28325798]
[17]
Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, Gerlach FM. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2018 Dec 17:12(12):CD013228. doi: 10.1002/14651858.CD013228. Epub 2018 Dec 17
[PubMed PMID: 30556900]
Level 1 (high-level) evidence
[18]
Shi C, Sun L, Bai R, Wang H, Liu D, Du J. Comparison of a twice daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes. Current medical research and opinion. 2019 Jun:35(6):1091-1096. doi: 10.1080/03007995.2018.1558853. Epub 2019 Jan 14
[PubMed PMID: 30550344]
Level 3 (low-level) evidence
[19]
Nunez Lopez YO, Retnakaran R, Zinman B, Pratley RE, Seyhan AA. Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. Molecular metabolism. 2019 Feb:20():63-78. doi: 10.1016/j.molmet.2018.11.003. Epub 2018 Nov 16
[PubMed PMID: 30503831]
Level 3 (low-level) evidence
[20]
Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, Fasciani I, Annibale P, Maggio R, Scarselli M. Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals (Basel, Switzerland). 2021 Mar 8:14(3):. doi: 10.3390/ph14030238. Epub 2021 Mar 8
[PubMed PMID: 33800403]
[21]
Amna S, Øhlenschlaeger T, Saedder EA, Sigaard JV, Bergmann TK. Review of clinical pharmacokinetics and pharmacodynamics of clonidine as an adjunct to opioids in palliative care. Basic & clinical pharmacology & toxicology. 2024 Apr:134(4):485-497. doi: 10.1111/bcpt.13979. Epub 2024 Jan 26
[PubMed PMID: 38275186]
[22]
Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Grassi G, Esler M. Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension (Dallas, Tex. : 1979). 2022 Jun:79(6):1153-1166. doi: 10.1161/HYPERTENSIONAHA.122.19020. Epub 2022 Apr 5
[PubMed PMID: 35378981]
[23]
Thu Kyaw M, Maung ZM. Hypokalemia-Induced Arrhythmia: A Case Series and Literature Review. Cureus. 2022 Mar:14(3):e22940. doi: 10.7759/cureus.22940. Epub 2022 Mar 7
[PubMed PMID: 35411269]
Level 2 (mid-level) evidence
[24]
Khiatah B, Frugoli A, Carlson D. The Clinical Caveat for Treating Persistent Hypokalemia in Diabetic Ketoacidosis. Cureus. 2023 Jul:15(7):e42272. doi: 10.7759/cureus.42272. Epub 2023 Jul 21
[PubMed PMID: 37605707]
[25]
Hong F, Xu P, Zhai Y. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. International journal of molecular sciences. 2018 Jul 27:19(8):. doi: 10.3390/ijms19082189. Epub 2018 Jul 27
[PubMed PMID: 30060458]
[26]
Sheikh IM, Hassan OA, Adam SM, Ali AI, Ogedegbe OJ, Tabowei G, Barbarawi A, Yussuf FM, Nor MA. Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review. Cureus. 2023 Oct:15(10):e46911. doi: 10.7759/cureus.46911. Epub 2023 Oct 12
[PubMed PMID: 37954768]
Level 1 (high-level) evidence
[27]
Johansen NJ, Christensen MB. A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Treatment Options. Basic & clinical pharmacology & toxicology. 2018 Jun:122(6):650-659. doi: 10.1111/bcpt.12957. Epub 2018 Feb 23
[PubMed PMID: 29316226]
Level 1 (high-level) evidence
[28]
Dall V. Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart. Arzneimittel-Forschung. 1999 May:49(5):463-70
[PubMed PMID: 10367110]
[29]
Gallagher A, Butler TJ, Home PD. The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes. Diabetes research and clinical practice. 2007 Jun:76(3):327-34
[PubMed PMID: 17092597]
[30]
Buse JB, Carlson AL, Komatsu M, Mosenzon O, Rose L, Liang B, Buchholtz K, Horio H, Kadowaki T. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. Diabetes, obesity & metabolism. 2018 Dec:20(12):2885-2893. doi: 10.1111/dom.13545. Epub 2018 Oct 10
[PubMed PMID: 30259644]
Level 1 (high-level) evidence